Medical Oncology

Prof. Dr. Gül Başaran

Doctor and researcher Acıbadem Altunizade Hastanesi İstanbul
Breast NeoplasmsNeoplasmsAdenocarcinomaLiver NeoplasmsCarcinoma, Ductal, BreastHodgkin DiseaseRectal NeoplasmsStomach Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 23 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Neoplasms 6 publications
  • Adenocarcinoma 4 publications
  • Liver Neoplasms 2 publications
  • Carcinoma, Ductal, Breast 2 publications
  • Hodgkin Disease 2 publications
  • Rectal Neoplasms 2 publications
  • Stomach Neoplasms 2 publications

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest the doctor lists on their own profile on the institution’s website. Source: acibadem.com.tr.

  • Meme Kanseri
  • Erkeklerde Meme Kanseri
  • İmmunoterapi ve Hedefe Yönelik Tedaviler
  • Lenfödem (Fil Hastalığı) Tedavisi

CV

Education and experience

From source

Experience

  • 2011Acıbadem Sağlık Grubuacibadem.com.tr
  • 2001 - 2003Universite Libre de Bruxelles, Cancerologieacibadem.com.tr
  • 1999 - 2003Marmara Üniversitesi Tıp Fakültesi / Tıbbi Onkolojiacibadem.com.tr

Education

  • 2003Marmara Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji, Üst Uzmanlıkacibadem.com.tr
  • 1999Marmara Üniversitesi Tıp Fakültesi, İç Hastalıkları, Uzmanlıkacibadem.com.tr
  • 1994İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, Tıp, Üniversiteacibadem.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologyacibadem.com.trFrom source
  • Department name at the sourceMeme Kliniği, Lenfödem (Fil Hastalığı) Tedavisiacibadem.com.trFrom source
  • InstitutionAcıbadem Altunizade Hastanesiacibadem.com.trFrom source
  • Area of workBreast NeoplasmsExtracted from 23 publications · Model version —From source
  • Publications139 publicationsOpenAlexFrom source
  • ORCID0000-0002-0775-6180ORCIDFrom source
  • Last synchronised4 November 2026 20:57https://www.acibadem.com.tr/doktor/gul-basaran/acibadem.com.tr

Scientific work

Publications on Breast Neoplasms

139 publications
Publications by year Most: 12, in 2024
  1. 2004: 9 publications
  2. 2005: 6 publications
  3. 2006: 6 publications
  4. 2007: 7 publications
  5. 2008: 4 publications
  6. 2009: 8 publications
  7. 2010: 6 publications
  8. 2011: 11 publications
  9. 2012: 4 publications
  10. 2013: 3 publications
  11. 2014: 4 publications
  12. 2015: 4 publications
  13. 2016: 2 publications
  14. 2017: 0 publications
  15. 2018: 6 publications
  16. 2019: 2 publications
  17. 2020: 7 publications
  18. 2021: 3 publications
  19. 2022: 6 publications
  20. 2023: 9 publications
  21. 2024: 12 publications
  22. 2025: 11 publications
  23. 2026: 9 publications

  1. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Therapeutic Advances in Medical Oncology, 2026

    DOI 10.1177/17588359261430583 PMID 41835339 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  2. Abstract PS5-02-08: Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-02-08 Source: OpenAlex

  3. Abstract PS5-05-14: Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-05-14 Source: OpenAlex

  4. Real-world associations of pathological complete response and survival with neoadjuvant pembrolizumab in early TNBC: a Turkish Oncology Group study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-47351-7 PMID 41933152 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  5. Abstract PS4-10-28: Neoadjuvant Chemoimmunotherapy in Early-Stage TNBC: Real-World Analysis of Predictors of pCR and Survival

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps4-10-28 Source: OpenAlex

  6. Antibody–drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure

    The Breast, 2026

    DOI 10.1016/j.breast.2026.104785 PMID 41980521 Open-access full textSource: OpenAlex

  7. First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.1002 3 citations (OpenAlex) Source: OpenAlex

  8. Abstract PS4-01-09: How does proteomics-based prognostic testing compare to genomic tests and online clinical risk prediction tools in early breast cancer patients?

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps4-01-09 Source: OpenAlex

  9. 415O First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Patient-reported outcomes (PROs) from TROPION-Breast02

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.107438 Open-access full textSource: OpenAlex

  10. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1639022 1 citation (OpenAlex) Open-access full textSource: OpenAlex

View all 139 publications